Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide in Open-angle Glaucoma
NCT05405868Phase 3Recruiting
- Sponsor
- University College London
- Start
- Jan 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in open-angle glaucoma (OAG) comparing Nicotinamide with Placebo (2 arms). Primary endpoint: Change in Visual Field Mean Deviation at 27 months. Started Jan 2024; status: recruiting.
02
Drugs
nicotinamide
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT05405868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405868.